Flu Season 2026, Week 53: Analysis of Accelerating Morbidity, Mortality, and Vaccine Policy in the US

Abstract

As the United States enters the second week of January 2026, the nation’s public health apparatus faces a converging crisis of biological evolution, epidemiological acceleration, and profound policy recalibration. The 2025–2026 influenza season has distinguished itself rapidly as a period of significant peril for the pediatric population. Surveillance data through the week ending January 3, 2026 (Week 53), reveals a sharp, accelerating trajectory in pediatric mortality, with confirmed deaths nearly doubling in a single week to reach a seasonal total of seventeen. This surge occurs against the backdrop of the record-breaking 2024–2025 season, which claimed 289 pediatric lives—the highest toll in non-pandemic history—and is currently driven by the dominance of the Influenza A(H3N2) subclade K variant.¹

Simultaneously, the immunological defense of the pediatric population is being reshaped by a seismic shift in federal health policy. On January 5, 2026, the Department of Health and Human Services (HHS) enacted a sweeping overhaul of the childhood immunization schedule, removing the universal recommendation for influenza vaccination in favor of a "shared clinical decision-making" model.⁴ This report provides an exhaustive examination of the current crisis, synthesizing virological data on the H3N2 subclade K variant, analyzing the immunological mechanisms of severe pediatric disease, and evaluating the potential public health consequences of the new federal vaccination guidelines. Through a detailed review of surveillance data, historical comparisons, and policy analysis, this article aims to elucidate the complex factors driving the accelerating morbidity and mortality among American children in the winter of 2026.

1. Introduction: The Convergence of Crises

The winter of 2025–2026 was anticipated to be a challenging season for respiratory health, following the establishment of the "tripledemic" pattern—the simultaneous circulation of COVID-19, Respiratory Syncytial Virus (RSV), and influenza—as the new seasonal norm.⁶ However, as the new year begins, the specific dynamics of the influenza epidemic have eclipsed other respiratory threats in their urgency and severity, particularly regarding the nation’s youngest citizens.

1.1 The Current Epidemiological Reality

As of January 11, 2026, the United States is in the grip of a rapidly intensifying influenza epidemic. The Centers for Disease Control and Prevention (CDC) estimates that the season has already resulted in at least 15 million symptomatic illnesses, 180,000 hospitalizations, and 7,400 deaths across the general population.² While these aggregate numbers suggest a moderately severe season for the general public, the burden is unevenly distributed, falling disproportionately heavily on the pediatric demographic.

The acceleration of severe outcomes in children has been abrupt. In the final weeks of 2025, pediatric deaths were accumulating at a concerning but steady rate. However, the transition into 2026 marked a disturbing inflection point. The CDC’s FluView report for Week 53 documented eight new pediatric deaths in a seven-day period, bringing the season's total to 17.² This sudden spike, occurring relatively early in the calendar year, signals that the pediatric epidemic may be entering a hyper-acute phase.

1.2 The Viral Agent: H3N2 Subclade K

The primary driver of this morbidity is the Influenza A(H3N2) virus, specifically a newly emerged genetic group known as "subclade K" (phylogenetically designated as J.2.4.1).⁷ Historically, seasons dominated by H3N2 viruses are associated with higher severity, particularly for the elderly and young children, compared to seasons dominated by H1N1 or Influenza B.⁸ The subclade K variant has rapidly displaced other circulating strains, accounting for over 90% of characterized H3N2 viruses in the United States by late December 2025.⁹ Its emergence has raised critical questions regarding antigenic drift—the process by which the virus mutates to escape immune detection—and the resultant efficacy of the season’s influenza vaccines.⁶

1.3 The Policy Shock

Perhaps the most significant variable in the 2025–2026 equation is not biological but administrative. In a move that has fundamentally altered the landscape of preventative care, the federal government announced a major restructuring of the childhood vaccine schedule on January 5, 2026. Citing a desire to align with international practices and "rebuild trust," the HHS removed the universal recommendation for the annual influenza vaccine for children, reclassifying it as a vaccine for "shared clinical decision-making".⁵ This policy shift, enacted in the midst of an accelerating epidemic, has sparked intense debate within the medical community regarding its potential to exacerbate vaccine hesitancy and widen immunity gaps in an already vulnerable population.³

This report will dissect these converging factors, moving from the broad epidemiological trends to the molecular mechanisms of the virus, and finally to the societal and policy implications that will define the outcome of the 2025–2026 influenza season.

2. The 2025–2026 Influenza Season: A Quantitative Overview

To understand the magnitude of the current crisis, one must first analyze the surveillance data provided by the CDC’s domestic influenza surveillance system. This system, which aggregates data from clinical laboratories, public health laboratories, and sentinel healthcare providers, provides the granular detail necessary to track the epidemic's trajectory.

2.1 Surveillance Metrics and Acceleration

The trajectory of the 2025–2026 season has been characterized by a steady rise in late autumn followed by a sharp acceleration in December and January.

• Case Burden: By Week 52 (ending December 27, 2025), the CDC estimated 11 million illnesses.¹¹ Just one week later, by Week 53, this estimate had jumped to 15 million illnesses.² This represents an increase of 4 million cases in a single week, indicating a high effective reproduction number (Rt) and widespread community transmission.

• Hospitalizations: The cumulative burden on the healthcare system is substantial. By Week 53, there were an estimated 180,000 flu-related hospitalizations.² The weekly rate of new admissions nearly doubled between Week 50 and Week 51, jumping from approximately 9,900 to over 19,000, signaling a rapid influx of severe cases that strains capacity, particularly in pediatric units.¹²

2.2 Virological Dominance

Laboratory data confirms that this season is overwhelmingly driven by Influenza A.

• Type Distribution: In Week 53, of the 1,259 viruses reported by public health laboratories, 97.1% (1,223) were Influenza A, while only 2.9% (36) were Influenza B.²

• Subtype Distribution: Among the Influenza A viruses that were subtyped, H3N2 is the undisputed dominant strain. In Week 53, H3N2 accounted for 92.3% of subtyped viruses, with H1N1pdm09 accounting for only 7.7%.²

• Implications of Dominance: The dominance of Influenza A(H3N2) is statistically correlated with more severe flu seasons. H3N2 viruses mutate more rapidly than H1N1 or B viruses, often leading to a greater degree of mismatch between the vaccine and the circulating strain. Furthermore, H3N2 tends to cause more severe clinical disease in "extreme" age groups—the very young (0–4 years) and the very old (65+ years).⁸

2.3 Geographic Spread

The epidemic is not localized but national in scope. By late December 2025, 48 jurisdictions (states and territories) reported "high" or "very high" respiratory illness activity.¹³ This widespread transmission facilitates the rapid propagation of the subclade K variant, leaving no region untouched and preventing the inter-state resource sharing (such as transferring pediatric ICU patients) that can sometimes mitigate regional surges. The ubiquity of the virus means that exposure risk is high in virtually every community across the country.¹⁴

3. The Pediatric Mortality Crisis: A Comparative Analysis

While the general population metrics indicate a "moderately severe" season, the data specific to pediatric mortality paints a far more alarming picture. The death of a child from influenza is a sentinel event, often representing the "tip of the iceberg" of severe pediatric morbidity.

3.1 The Surge in Deaths

The progression of pediatric deaths in the 2025–2026 season has shown a disturbing acceleration.

• Early Season: throughout October and November (Weeks 40–47), reports of pediatric deaths were sporadic, typical of the early season.¹⁵

• Mid-Season: By Week 51, the CDC reported five deaths in a single week.¹⁶

• The January Spike: The Week 53 report (early January) documented eight additional deaths, bringing the total to 17.²

While 17 deaths may seem numerically small compared to adult mortality, in the context of pediatric epidemiology, this is a significant and rapid accumulation. For comparison, many mild flu seasons conclude with fewer than 50 pediatric deaths total. To reach 17 by early January suggests a trajectory that could rival the most severe seasons on record.¹⁷

3.2 The Shadow of 2024–2025

The current crisis cannot be viewed in isolation; it is occurring in the immediate aftermath of a historic tragedy. The 2024–2025 flu season set a grim record for pediatric mortality.

• Record Toll: A total of 289 children died from influenza-associated causes in the 2024–2025 season.¹

• Historical Context: This figure surpassed the previous record of 288 deaths set during the 2009 H1N1 pandemic.¹⁸ It was the deadliest season for children since mandatory reporting began in 2004.

• Demographic Insights: Of the children who died in the 2024–2025 season, approximately 50% had underlying medical conditions, meaning that half were previously healthy children. Furthermore, 89% of these children were not fully vaccinated.¹⁹

The proximity of the 2025–2026 season to this record-breaking event suggests that the factors driving high pediatric mortality—whether they be viral virulence, low population immunity, or gaps in healthcare access—have not been resolved. In fact, the emergence of H3N2 subclade K suggests they may have intensified.

3.3 Hospitalization Rates in Children

Beyond mortality, hospitalization rates provide a broader measure of severity. The cumulative hospitalization rate for children aged 0–4 years is currently 32.6 per 100,000 population.¹⁵ This age group has the second-highest hospitalization rate of any demographic, trailing only adults over 65. This bimodal distribution of severity is characteristic of H3N2 seasons but highlights the extreme vulnerability of the youngest children, who lack the reservoir of cross-reactive antibodies that older children and adults may have developed from years of flu exposure.²¹

Table 1: Pediatric Influenza Mortality Comparison (Selected Seasons)

Season	Dominant Virus	Total Pediatric Deaths	Key Characteristics
2025–2026	H3N2 (Subclade K)	17 (as of Week 53)	Accelerating trajectory; rapid onset in Jan 2026 2
2024–2025	H1N1 / H3N2	289	Record high for non-pandemic season 1
2023–2024	H1N1	210	High severity 22
2019–2020	H1N1 / B	199	High severity pre-pandemic 23
2017–2018	H3N2	188	Classic severe H3N2 season 24
2009–2010	H1N1pdm09	288	Pandemic season 18
2011–2012	H3N2	37	Mild season 24

4. Virological Underpinnings: The Rise of H3N2 Subclade K

The engine of the 2025–2026 epidemic is a specific viral variant: Influenza A(H3N2) subclade K. Understanding the biology of this variant is essential to grasping why it poses such a challenge to pediatric health and vaccine effectiveness.

4.1 Taxonomy and Emergence

Influenza viruses are constantly evolving. The H3N2 subtype is particularly prone to rapid genetic change. The current dominant strain, known technically as subclade J.2.4.1 but widely referred to as "subclade K," emerged from the J.2 lineage.²⁵ It was first identified in the Southern Hemisphere during their 2025 flu season, where it demonstrated a significant fitness advantage, rapidly outcompeting other strains in countries like Australia and New Zealand.²⁵

4.2 Mechanism of Antigenic Drift

The success of subclade K is driven by "antigenic drift." This is a process where the virus accumulates mutations in the genes coding for its surface proteins, primarily hemagglutinin (HA). The HA protein is the main target of the human immune system; antibodies bind to the "head" of the HA protein to neutralize the virus.

Subclade K possesses a constellation of specific amino acid substitutions in the HA protein, including mutations at positions T135K, K189R, S144N, N145S, and I160K.²⁶ These positions are located in key antigenic sites (epitopes) where antibodies typically bind. By changing the shape of these sites, the virus effectively "disguises" itself. Antibodies generated by previous infections with older H3N2 strains, or by vaccines formulated against older strains, may struggle to recognize and bind to the mutated HA of subclade K.⁶

4.3 Genetic Dominance in the US

In the United States, the displacement of other strains by subclade K has been nearly total. Among H3N2 viruses genetically characterized by the CDC since September 2025, over 90% belong to subclade K.² This rapid takeover suggests that the variant is highly transmissible and capable of evading the existing population immunity. It essentially found a "path of least resistance" through the US population, allowing for explosive growth in case numbers.⁶

4.4 "Super Flu" or Just Evolution?

The media has occasionally dubbed subclade K a "super flu," but virologists urge caution with such terms. There is currently no definitive evidence that subclade K is intrinsically more virulent—meaning it does not necessarily cause more severe damage to cells on a one-to-one basis than other H3N2 viruses.⁸ However, because it is an H3N2 virus (which is baseline more severe) and because it is highly immune-evasive (infecting more people), the net result is a higher number of severe cases and deaths. It is a numbers game: a virus that infects 20 million people will kill more children than a virus that infects 10 million, even if the per-case fatality rate is identical.¹¹

5. Immunological Mechanisms of Pediatric Severity

Why does H3N2, and subclade K in particular, kill children? The answer lies in the unique immunological status of the pediatric host. Unlike adults, who have decades of "immunological memory" from various flu infections, young children are often "immunologically naive."

5.1 The Naive Host and Viral Replication

For a child under the age of five, the 2025–2026 season may represent their first ever encounter with an influenza virus. In a naive host, the body has no pre-existing antibodies to intercept the virus. This allows the virus to replicate unchecked in the respiratory tract for several days before the adaptive immune system (B cells and T cells) can mount a defense.²¹ During this window of unchecked replication, the virus causes direct cytopathic damage to the epithelial cells lining the airways, stripping away the protective barrier of the lungs and predisposing the child to secondary bacterial infections like bacterial pneumonia—a common cause of flu-related death.

5.2 The "Cytokine Storm" Mechanism

In some children, the immune system's attempt to catch up leads to a dysregulated hyper-inflammatory response known as a "cytokine storm." When the immune system finally detects the massive viral load, it releases a flood of pro-inflammatory signaling molecules (cytokines) such as Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF-alpha), and Interferons.²⁸

While cytokines are necessary to fight infection, an excessive "storm" causes collateral damage. It can lead to:

• Diffuse Alveolar Damage: The inflammation causes the air sacs in the lungs to fill with fluid and cellular debris, blocking oxygen exchange (Acute Respiratory Distress Syndrome, or ARDS).²⁹

• Systemic Vasodilation: This can lead to a dangerous drop in blood pressure (shock).

• Multi-Organ Failure: The kidneys, liver, and heart can be damaged by the systemic inflammation and lack of oxygen.

Research suggests that H3N2 infections may be more prone to triggering this specific type of immune dysregulation in children compared to other strains, due to age-related differences in innate immune regulation.³⁰ The result is that a healthy child can deteriorate from a fever to life-threatening respiratory failure in a matter of hours.

5.3 Neurological Complications: Acute Necrotizing Encephalopathy

Another severe mechanism observed in pediatric H3N2 deaths is Acute Necrotizing Encephalopathy (ANE).³¹ This is a rare but devastating condition where the viral infection triggers a rapid destruction of brain tissue, particularly in the thalamus and brainstem. It is not necessarily caused by the virus invading the brain, but rather by the "cytokine storm" affecting the central nervous system. The rapid onset of seizures and coma in a child with the flu is a hallmark of this condition, and it is historically more common during H3N2 epidemics.

6. The Vaccination Paradox: Mismatch vs. Effectiveness

A central narrative of the 2025–2026 season is the tension between the virus's evolution and the vaccine's composition. With subclade K showing significant drift, there were initial fears that the vaccine would be ineffective. However, the data reveals a more complex and hopeful reality.

6.1 The "Mismatch" on Paper

The 2025–2026 Northern Hemisphere influenza vaccine is trivalent, containing components for H1N1, H3N2, and Influenza B. The H3N2 component was selected in early 2025 based on the A/Croatia/10136RV/2023-like virus.³² However, as subclade K evolved, it drifted away from this reference strain. Laboratory tests using ferret antisera showed that antibodies raised against the vaccine strain had reduced reactivity against subclade K.²⁶ In technical terms, this is an "antigenic mismatch."

6.2 The Effectiveness in Reality

Despite the laboratory mismatch, real-world Vaccine Effectiveness (VE) data has been surprisingly robust, particularly for children. Data from the United Kingdom, which experienced the subclade K wave earlier than the US, indicates that the current vaccine is providing substantial protection against severe outcomes.

• Pediatric VE: Estimates from the UK Health Security Agency suggest a VE of 70–75% against hospitalization for children.⁷

• Adult VE: In contrast, VE for adults is lower, estimated at roughly 30–40%.⁷

6.3 Explaining the Success in Children

Why is the vaccine working well in children despite the mismatch?

1. Broader Immune Response: In children, especially those receiving live attenuated vaccines (nasal spray) or adjuvanted vaccines, the immune response may be broader, targeting parts of the virus that remain conserved even as the head of the HA protein mutates.²⁷

2. High Titer Response: Children often mount a very vigorous antibody response to vaccination, which can overcome the lower binding affinity caused by the mismatch.

3. Prevention of Severity: Even if the vaccine does not perfectly prevent infection (getting a runny nose), it primes the immune system sufficiently to prevent the viral replication from reaching the threshold that triggers the deadly "cytokine storm." It turns a life-threatening illness into a manageable one.³³

This data leads to a critical conclusion: The surge in pediatric deaths is not due to vaccine failure. The tool works. The tragedy lies in the fact that it is not being used.

6.4 The Coverage Gap

The current pediatric vaccination rate in the US is approximately 42.5%.³⁴ This means nearly 60% of American children are navigating a severe H3N2 epidemic with zero vaccine-derived protection. This coverage is significantly lower than the ~60% rates seen in pre-pandemic years like 2017–2018.³⁵ The 17 deaths reported so far are occurring almost exclusively in this pool of unvaccinated or under-vaccinated children, mirroring the 2024–2025 season where 89% of deceased children were unvaccinated.²⁰

7. The Policy Landscape: The 2026 HHS Overhaul

In a cruel twist of timing, the biological challenge of H3N2 subclade K has coincided with a fundamental dismantling of the policy infrastructure that supports pediatric vaccination. On January 5, 2026, the Department of Health and Human Services (HHS) enacted a controversial overhaul of the US childhood immunization schedule.

7.1 The "Denmark Model" Shift

The new HHS directive, signed by Acting CDC Director Jim O’Neill following a presidential memorandum, seeks to align US vaccination recommendations with those of "peer, developed nations," explicitly citing Denmark as a model.⁴ Denmark has historically maintained a leaner childhood vaccine schedule than the US.

Under the new guidelines:

• Routine Recommendations Reduced: The number of vaccines routinely recommended for all children was cut from 17 to 11.

• The Removal of Flu: The influenza vaccine was removed from the "universally recommended" list.

• New Category: Influenza (along with COVID-19, Rotavirus, Hepatitis A, and Hepatitis B) was reclassified into a category of "shared clinical decision-making".⁵

7.2 What "Shared Clinical Decision-Making" Means

Previously, the guidance was clear: "CDC recommends everyone 6 months and older get a flu shot." This was a default standard of care. Under the new "shared clinical decision-making" framework, the vaccine is no longer a default. It is an option to be discussed. The provider must assess the individual risk and the parent's preference before administering the vaccine.

While this sounds like a move toward personalized medicine, in practice, it creates a massive barrier.

1. Friction: It adds time to pediatric appointments that are already rushed, leading providers to skip the conversation.

2. Perception of Risk: By removing the "universal" label, the government signals to parents that the flu is not a serious threat for the average child—a message that is diametrically opposed to the epidemiological reality of H3N2 subclade K.³

3. Insurance Implications: While the administration claims insurance will still cover these vaccines, the removal of the "routine" designation creates ambiguity that could lead to coverage gaps or copays in the future.³⁶

7.3 The Medical Community’s Backlash

The reaction from the medical establishment has been swift and condemnatory. The American Academy of Pediatrics (AAP) called the changes "dangerous and unnecessary".³⁸ The American College of Physicians warned that "abandoning the evidence-based process is a potentially deadly decision".⁵

Dr. Sean O'Leary, chair of the AAP Committee on Infectious Diseases, noted the profound disconnect between the policy and the reality: "To back off on a flu recommendation in the midst of a pretty severe flu year seems to me to be pretty tone deaf".³ The concern is that this policy change validates vaccine hesitancy and will drive coverage rates—already low at 42.5%—down even further, just as the H3N2 wave is cresting.

8. Societal and Behavioral Drivers of the Epidemic

The accelerating mortality rate is not just a function of biology or policy, but of human behavior. The US population in 2026 is suffering from a unique form of fatigue and skepticism that creates fertile ground for the virus.

8.1 Vaccine Fatigue and "Alert Fatigue"

After years of the COVID-19 pandemic and subsequent "tripledemic" warnings, many parents are experiencing "alert fatigue." The constant urgency of public health messaging has led to desensitization. When every respiratory season is billed as a crisis, the warnings about H3N2 subclade K may be tuned out as just more noise.³⁹

8.2 The Erosion of Trust

The HHS policy shift explicitly aimed to "rebuild trust" by reducing the number of vaccines, based on the theory that a lighter schedule would be more palatable to hesitant parents.⁴ However, infectious disease experts argue this backfires by legitimizing the idea that vaccines are unnecessary. By treating the flu shot as optional/conditional, the government may inadvertently confirm the suspicions of vaccine-skeptical parents, leading them to forego the shot entirely.

8.3 Low Perception of Flu Severity

Despite the data showing 289 deaths last season, a pervasive myth persists that the flu is a mild inconvenience. This is exacerbated by the fact that many adults get the flu and recover quickly. Parents may project their own low risk onto their children, failing to realize that the pediatric immune system handles H3N2 very differently (as discussed in Section 5). The lack of visceral awareness of the danger—until it strikes their community—remains a major barrier to uptake.³⁹

9. Conclusion

As of January 11, 2026, the United States stands at a precipice. The 2025–2026 influenza season has all the ingredients of a public health disaster for the pediatric population:

1. A formidable viral adversary: H3N2 subclade K, a highly transmissible and immune-evasive variant.

2. A vulnerable population: Millions of immunologically naive children with no vaccine protection (42.5% coverage).

3. A policy vacuum: The removal of universal vaccination recommendations at the precise moment they are most needed.

The data is unequivocal. Seventeen children have already died, with the rate of death accelerating rapidly in the first weeks of the new year. If the trajectory follows that of the 2024–2025 season, hundreds more children could perish before the spring thaw.

However, the data also offers a solution. The vaccine, despite the mismatch, is 70–75% effective at keeping children out of the hospital. The mechanism of death—the cytokine storm—can be prevented by the priming of the immune system that vaccination provides.

The path forward requires an immediate and unified response from pediatricians, public health officials, and parents to look past the confused policy signals and focus on the biological reality. The flu is not a trivial illness in 2026. It is a clear and present danger to American children, and the tools to stop it are available, provided the will exists to use them.

Works cited

1. Nine Children Die During 2025-2026 Flu Season, accessed January 11, 2026, https://www.vax-before-travel.com/2026/01/07/nine-children-die-during-2025-2026-flu-season

2. Weekly US Influenza Surveillance Report: Key Updates for Week 53, ending January 3, 2026 | FluView | CDC, accessed January 11, 2026, https://www.cdc.gov/fluview/surveillance/2025-week-53.html

3. CDC: 9 children have died of flu this season; previous season sets record, accessed January 11, 2026, https://publications.aap.org/aapnews/news/34114/CDC-9-children-have-died-of-flu-this-season

4. CDC Acts on Presidential Memorandum to Update Childhood Immunization Schedule, accessed January 11, 2026, https://www.hhs.gov/press-room/cdc-acts-presidential-memorandum-update-childhood-immunization-schedule.html

5. HHS announces unprecedented overhaul of US childhood vaccine schedule - CIDRAP, accessed January 11, 2026, https://www.cidrap.umn.edu/childhood-vaccines/hhs-announces-unprecedented-overhaul-us-childhood-vaccine-schedule

6. Virus Transmission Trends, Winter 2025–26, accessed January 11, 2026, https://publichealth.jhu.edu/2025/virus-transmission-trends-winter-2025-26

7. With an absent CDC and mismatched 'subclade K' flu strain, experts face upcoming season with uncertainty | CIDRAP, accessed January 11, 2026, https://www.cidrap.umn.edu/influenza-vaccines/absent-cdc-and-mismatched-subclade-k-flu-strain-experts-face-upcoming-season

8. “Superflu” or same old flu? How subclade K influenza is playing out worldwide, accessed January 11, 2026, https://www.gavi.org/vaccineswork/superflu-or-same-old-flu-how-subclade-k-influenza-playing-out-worldwide

9. Weekly US Influenza Surveillance Report: Key Updates for Week 52, ending December 27, 2025 | FluView | CDC, accessed January 11, 2026, https://www.cdc.gov/fluview/surveillance/2025-week-52.html

10. US cuts the number of vaccines recommended for every child, a move slammed by physicians, accessed January 11, 2026, https://www.news4jax.com/health/2026/01/05/us-drops-the-number-of-vaccines-it-recommends-for-every-child/

11. Mapped: 'Super flu' variant driving surge in cases, hospitalizations, accessed January 11, 2026, https://www.advisory.com/daily-briefing/2026/01/06/flu-update

12. US Influenza Activity Accelerates Into the New Year as Hospitalizations Rise, accessed January 11, 2026, https://www.contagionlive.com/view/us-influenza-activity-accelerates-into-the-new-year-as-hospitalizations-rise

13. flu deaths rising influenza update, accessed January 11, 2026, https://www.specialtypharmacycontinuum.com/Online-First/Article/01-26/flu-deaths-rising-influenza-update/79335

14. US flu activity takes big jump as 2 deaths in kids confirmed, accessed January 11, 2026, https://www.cidrap.umn.edu/influenza-general/us-flu-activity-takes-big-jump-2-deaths-kids-confirmed

15. Influenza Surges in US | RT - Respiratory Therapy, accessed January 11, 2026, https://respiratory-therapy.com/disorders-diseases/infectious-diseases/influenza/cdc-influenza-update-2025-week-52/

16. Weekly US Influenza Surveillance Report: Key Updates for Week 51, ending December 20, 2025 | FluView | CDC, accessed January 11, 2026, https://www.cdc.gov/fluview/surveillance/2025-week-51.html

17. Pediatric flu deaths hit 15-year high | AHA News, accessed January 11, 2026, https://www.aha.org/news/headline/2025-05-05-pediatric-flu-deaths-hit-15-year-high

18. 2024-2025 PEDIATRIC FLU DEATHS SURPASS PREVIOUS RECORD, accessed January 11, 2026, https://familiesfightingflu.org/2024-2025-pediatric-flu-deaths-surpass-previous-record/

19. Vaccine Update: What to Expect for the 2025-2026 Influenza Season - Children's Mercy, accessed January 11, 2026, https://www.childrensmercy.org/health-care-providers/refer-or-manage-a-patient/connect-with-childrens-mercy/newsletter-the-link/the-link-2025/the-link---november-2025/vaccine-update-what-to-expect-for-the-2025-2026-influenza-season/

20. Influenza-Associated Pediatric Deaths — United States, 2024–25 Influenza Season | MMWR - CDC, accessed January 11, 2026, https://www.cdc.gov/mmwr/volumes/74/wr/mm7436a2.htm

21. Influenza: Toward understanding the immune response in the young - Frontiers, accessed January 11, 2026, https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2022.953150/full

22. Influenza-associated Pediatric Mortality - CDC, accessed January 11, 2026, https://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html

23. More than 100 Flu-Related Deaths in Children Reported So Far This Season - CDC, accessed January 11, 2026, https://www.cdc.gov/flu/whats-new/2023-2024-pediatric-flu-deaths.html

24. Summary of the 2017-2018 Influenza Season - CDC Archive, accessed January 11, 2026, https://archive.cdc.gov/www_cdc_gov/flu/about/season/flu-season-2017-2018.htm

25. Seasonal influenza - Global situation - World Health Organization (WHO), accessed January 11, 2026, https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON586

26. Antibodies elicited by the 2025-2026 influenza vaccine in humans - medRxiv, accessed January 11, 2026, https://www.medrxiv.org/content/10.64898/2026.01.05.26343449v1.full.pdf

27. Early influenza virus characterisation and vaccine effectiveness in England in autumn 2025, a period dominated by influenza A(H3N2) subclade K - PMC - NIH, accessed January 11, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12639273/

28. The cytokine storm of severe influenza and development of immunomodulatory therapy - PMC - PubMed Central, accessed January 11, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC4711683/

29. The Mechanism behind Influenza Virus Cytokine Storm - PMC - PubMed Central, accessed January 11, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC8310017/

30. Influenza: Toward understanding the immune response in the young - PMC - NIH, accessed January 11, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9437304/

31. Reports of Encephalopathy Among Children with Influenza-Associated Mortality - United States, 2010-11 Through 2024-25 Influenza Seasons - PubMed, accessed January 11, 2026, https://pubmed.ncbi.nlm.nih.gov/40014654/

32. 2025–2026 Flu Season | Influenza (Flu) - CDC, accessed January 11, 2026, https://www.cdc.gov/flu/season/2025-2026.html

33. H3N2 “Subclade K” Is Spreading. Here's What It Means for Severity, Vaccines, and Treatment - Belfer Center, accessed January 11, 2026, https://www.belfercenter.org/research-analysis/h3n2-subclade-k-spreading-heres-what-it-means-severity-vaccines-and-treatment

34. Weekly Flu Vaccination Dashboard | FluVaxView - CDC, accessed January 11, 2026, https://www.cdc.gov/fluvaxview/dashboard/index.html

35. Reported Flu Deaths in Children Surpass 100 for 2016-17 - CDC Archive, accessed January 11, 2026, https://archive.cdc.gov/www_cdc_gov/flu/spotlights/archived/reported-flu-deaths-children.htm

36. CDC overhauls childhood immunization schedule - RISE Health, accessed January 11, 2026, https://www.risehealth.org/insights-articles/cdc-overhauls-childhood-immunization-schedule/

37. U.S. Slashes Recommended Childhood Vaccines From 17 to 11, accessed January 11, 2026, https://www.everydayhealth.com/general-health/us-slashes-recommended-childhood-vaccines-to-eleven-from-seventeen/

38. HHS’s Abridged Vaccine Recommendations, accessed January 11, 2026, https://publichealth.jhu.edu/2026/hhss-abridged-vaccine-recommendations

39. The ominous new 'K' flu variant is spreading as flu shot rates fall - UCHealth, accessed January 11, 2026, https://www.uchealth.org/today/k-flu-variant-spreads-as-flu-shot-rates-fall/